Wikipedia
Caplacizumab
Caplacizumab ( INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.
This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.
It is an anti- von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported.